Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Tammy Boyce, MEd

Dynavax Technologies Corporation

Disclosure(s): Dynavax Technologies Corporation: Employee, Stocks/Bonds

Poster(s):

121 - Safety, Tolerability, and Pertussis Immunogenicity Findings From a Randomized, Participant-Blinded, Active-Controlled, Dose-Escalating, Phase 1 Trial of a Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018 CpG Adjuvanted) Compared With Boostrix in Healthy Adults Aged 18 to 22 Years
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET